2.1. Introduction 2.2. Types of assets purchased 2.3. Trends in asset purchase deals since 2009 2.3. Reasons for entering into asset purchase partnering deals 2.3.1. Business assets 2.3.2. Product assets 2.3.3. Royalty assets 2.3.4.Technology assets 2.4 The emergence of royalty asset purchase deals 2.4.1. Primary players in royalty asset purchase deals 2.4.2. Recent royalty asset purchase deals 2.4.3. The future of royalty asset purchase deals 2.5. The role of IP auction houses in asset purchase deals 2.5.1. Leading IP auction companies 2.6. The future of asset purchase agreements

Chapter 3 – Overview of asset purchase deal structure

3.1. Introduction 3.2. Asset purchase agreement structure 3.3. Example asset purchase agreements 3.3.1. Case study 1: Product asset: QLT – Valeant Pharmaceuticals 3.3.2. Case study 2: Business asset: Enzon Pharmaceuticals – Sigma-Tau 3.4. Anatomy of a royalty asset purchase agreement 3.5. Example royalty asset purchase agreements 3.5.1. Case study 3: Royalty asset: DRI Capital – NPS Pharmaceuticals

Chapter 4 – Leading asset purchase deals

4.1. Introduction 4.2. Top asset purchase deals by value 4.3. Most active asset purchase dealmakers 4.4. Bigpharma asset purchase deal activity 4.5. Bigbiotech asset purchase deal activity

5.1. Introduction 5.2. How to use asset purchase deals 5.3. Bigpharma company asset purchase deal profiles Abbott Actavis Amgen Astellas AstraZeneca Baxter International Bayer Biogen Idec Boehringer Ingelheim Bristol-Myers Squibb Celgene Daiichi Sankyo Eli Lilly Endo Pharmaceuticals Forest Laboratories Fresenius Gilead Sciences GlaxoSmithKline Grifols Hospira Johnson & Johnson Kyowa Hakko Kirin Lundbeck Merck & Co Merck KGaA Mylan Novartis Novo Nordisk Pfizer Roche Sanofi Servier Shionogi Shire

Chapter 6 – Bigbiotech company asset purchase deals

6.1. Introduction 6.2. How to use bigbiotech partnering deals 6.3. Bigbiotech asset purchase partnering company profiles Acorda Therapeutics Actelion Alexion Pharmaceuticals Biocon BioMarin Pharmaceuticals Celgene Dendreon Elan Emergent BioSolutions Galapagos Gilead Sciences Grifols Ipsen Novo Nordisk PDL BioPharma Regeneron Pharmaceuticals SciClone Pharmaceuticals Shire Spectrum Pharmaceuticals ViroPharma

Chapter 7 – Asset purchase contracts directory

7.1. Introduction 7.2. Company A-Z Acadia Healthcare Accentia Biopharmaceuticals Actient Pharmaceuticals Agencourt Bioscience

© 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Agilent Technologies AJG Brands Alexza Pharmaceuticals Altair Nanotechnologies Alveolus Ambit Biosciences American Medical Systems American Red Cross Ampio Pharmaceuticals Apex Laboratories Applied Genetic Technologies Apricus Biosciences Arizona Heart Hospital Avalon Pharmaceuticals Axial Biotech Bayer Bayer Schering Pharma Beckman Coulter Beckman Coulter Genomics Bio-GAL Bio-Imaging Technologies Bio Key BioBalance BioClinica Biocodex BioDelivery Sciences Biolase Technology BioOne BioPharma Manufacturing Solutions Biotage Biovail Biovail Laboratories Boston Scientific Bostwick Laboratories BP Bristol-Myers Squibb Caliper Life Sciences Cambridge Laboratories Caraco Pharmaceuticals © 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Cardium Therapeutics Cary Pharmaceuticals Cas Medical Systems Celera Cell Therapeutics Celsion Cerus Clinical Data Codexis Cogenics Columbia Laboratories CombinatoRx Commonwealth Biotechnologies Conceptus Cornerstone Therapeutics Cortex Pharmaceuticals Cragmont Pharmaceuticals Crawford Healthcare Cynosure Cytodyn CytRx Cytyc DeCODE Genetics Devicor Medical Products Diodem DiscoveRx DSM Dynavax Technologies ECR Pharmaceuticals Edgewater Capital Partners EKR Therapeutics Elan Electronics For Imaging Elite Pharmaceuticals Enox BioPharma Enterologics Entest BioMedical Enzon Pharmaceuticals EPIX Pharmaceuticals © 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Erin Mills Investment Escalon Vascular Access Evonik Industries Evotec Exact Sciences Express Scripts Facet Biotechnology FMI Holdings Forbes Medi-Tech Forest Laboratories Gene Logic Genzyme Genzyme Genetics Gilead Sciences GlaxoSmithKline GliaMed Graceway Pharmaceuticals Hadasit Medical Research Services and Development Haemonetics Corporation Hansen Medical HemaCare Hi-Tech Pharmacal Hologic Hongrui Pharmaceuticals Hospira HOYA Corporation Hyperion Therapeutics Icagen ICU Medical Ikaria ImaRX InnerCool Therapies Inolife Technologies Inovio Pharmaceuticals Insmed Inc IntelGenx InterAct911 Interleukin Genetics InterMune © 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Intervet Intrexon Intuitive Surgical ISonix Janssen Pharmaceutical JDSU Johnson & Johnson KV Pharmaceutical La Jolla Pharmaceutical LabCorp Laiyang Jiangbo Pharmaceutical Lantheus Medical Imaging Laxai Pharma Lightlake Therapeutics Lorus Therapeutics Lundbeck Madrona Ventures Mallinckrodt Manhattan Scientifics MannKind Biopharmaceuticals Maxygen McDonald Animal Hospital McNeil PPC Mead Johnson Nutrition MedCath Medicis MediVision Medical Imaging Merck and Co Merial Merit Medical Systems Mesa Labs Methodist Healthcare System MHT Microbix Biosystems MiddleBrook Pharmaceutical Mikah Pharma Misonix Momenta Pharmaceuticals My Complete Care © 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Myriad Pharmaceuticals Mystaire Nabi Biopharmaceuticals Neoprobe Neuromed Nitricare Novartis NuVasive Ocimum Biosolutions Olympus OncoSec Medical Ophthalmic Imaging Systems OPKO Health Oramed Pharmaceuticals Ore Pharmaceuticals Orphan Therapeutics Orphazyme Ortho Dermatologics Oscient Pharmaceuticals OSI Optoelectronics OSR Solutions Pall Corporation Panacos Pharmaceuticals Paravid Particle Dynamics PDL BioPharma Pep Products Pet Pointers Pfizer PharmaChem Pharmacyclics Pharmos Philips Precision Optics Prestige Brands Procter & Gamble Procter & Gamble Pharmaceuticals Progenics Pharmaceuticals Progentix Orthobiology © 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Prothena Biosciences QLT QLT USA Radius Medical Technologies RegenoCELL Therapeutics Reperio Pharmaceuticals Roche Royal Philips Electronics S*Bio Saga Investments Sanofi-Aventis Schering-Plough SciClone Pharmaceuticals Scientific Nanomedicine Senetek Senior Scientific Shaanxi Biostar Biotech Sigma-Tau Skinvera Spectrum Pharmaceuticals Stem Cell Sciences StemCells Strakan Sun Pharmaceutical SurModics SurModics Pharmaceuticals Symphony Allegro Symphony Dynamo Targeted Genetics Texsan Heart Hospital The Regents of the University of California TheraVitae Tolmar Transdel Pharmaceuticals TranSenda Transgenomic TrovaGene TTFactor Ucyclyd Pharma © 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Uluru USHIFU Valeant Pharmaceuticals Vanguard Health Systems Vascular Solutions Verenium Victory Pharma WA 32609 Warner Chilcott Watson Pharmaceuticals Wellpoint Wyeth Xi’an Meipude Bio-Technology XTL Biopharmaceuticals Ziarco Pharma 7.3. By stage of development Discovery Formulation Marketed Phase I Phase II Phase III Preclinical Regulatory 7.4. By therapeutic target Anaesthetics Cardiovascular Central Nervous System Dental Dermatology Gastrointestinal Genetic disorders Genitourinary Gynaecology Hematology Hospital care Immunology Infectives Metabolic © 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Musculoskeletal Obstetrics Oncology Ophthalmics Pediatrics Psychiatry Public Health Respiratory Sexual Health 7.5. By technology type Analysis Assays Bioinformatics Biological compounds Biomarkers Biomaterials Bioprocessing Blood products Clinical testing Devices Diagnostics Discovery tools Drug delivery Enabling technology Enviromental Equipment Facilities Gene therapy Genomics Implant Industrial chemicals Nanotechnology Natural product Oligonucleotide Orphan drug Peptides Personalised medicine Pharmacogenomics Processes © 2012 – CurrentPartnering, a division of Wildwood Ventures Limited. This brochure is published by Wildwood Ventures Ltd. Proteomics Radio/Chemo-therapy Recombinant DNA Regenerative medicine Research services Research supplies RNA therapeutics Screening Small molecules Software tools Stem cells Vaccines About Wildwood Ventures Current Partnering Current Agreements Recent report titles from CurrentPartnering Order Form – Reports Order Form – Reports

Appendices

Appendix 1- Company A-Z Appendix 2- By therapy area Appendix 3-By stage of development at signing Appendix 4- By technology type Appendix 5- Asset purchase dealmaking references Appendix 6- Resources Appendic 7- Deal type definitions Appendix 8-Example asset purchase contract document

Figure 1: Definition of assets purchased Figure 2: Trends in asset purchase deal announcements, 2009-2013 Figure 3: Leading royalty asset investors Figure 4: Recent royalty asset purchase agreements Figure 5: Leading IP auction companies Figure 6: Components of the asset purchase deal structure Figure 7: Components of the royalty asset purchase deal structure Figure 8: Top asset purchase deals by value since 2009 Figure 9: Most active asset purchase dealmakers 2009-2013 Figure 10: Bigpharma – top 50 – asset purchase deals 2009 to 2013 Figure 11: Bigpharma asset purchase deal frequency - 2009 to 2013 Figure 12: Bigbiotech – top 50 – asset purchase deals 2009 to 2013 Figure 13: Bigbiotech asset purchase deal frequency - 2009 to 2013

Table of Contents